Clinical trial · Interventional
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer
Evaluation of the Efficacy of a Homeopathic Protocol to Reduce the Onset or Aggravation of Joint Pain or Stiffness Following the Taking of Anti-aromatases (AI) in Patients With Non-metastatic Breast Cancer
NCT04408560CI-TRIAL-00060915ARHOMA2completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Interventional, randomised, prospective, monocentric study
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
| Joint Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paracetamol (drug analgesic class1) | Other | — | UNRESOLVED |
| Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Groupe A with homéopathic treatment
- description
- Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
- interventionNames
- Drug: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)
- Other: paracetamol (drug analgesic class1)
- type
- SHAM_COMPARATOR
- label
- Groupe B without homeopathic treatment
- description
- Conventional treatment : paracetamol (drug analgesic class1)
- interventionNames
- Other: paracetamol (drug analgesic class1)
Primary outcomes (1)
- measure
- Evolution of the score of "most intense pain" during the first 3 months of treatment with AI
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * menopausal patient * achieved histologically confirmed non-metastatic breast cancer with positive hormonal receptors * starting an adjuvant anti-hormonal treatment with an AI * patient benefiting from a social protection scheme * patient mastering the French language -signature of free and informed consent - Exclusion Criteria: * patient whose treatment with chemotherapy or radiotherapy is ongoing or anticipated during the theoretical period of the study or patient who has completed her chemotherapy treatment within a period of less than 4 weeks prior to the inclusion visit * patient with proven inflammatory rheumatism already diagnosed with rheumatoid arthritis, lupus, psoriatic rheumatism, ankylosing spondylitis -concomitant treatment with other complementary medicines (excepted Vitamin D), unless the treatment has been stable for at least 1 month. * current treatment with narcotic drugs or corticosteroids * patient with overexpressing breast cancer HER2
References
Publications (0)
Data not yet available
No reference posted for this study.